Business Description
Oculis Holding AG
ISIN : CH1242303498
Description
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 151.62 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -101.8 | |||||
| 3-Year EPS without NRI Growth Rate | -54.8 | |||||
| 3-Year FCF Growth Rate | -71.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 28.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59 | |||||
| 9-Day RSI | 58.04 | |||||
| 14-Day RSI | 55.59 | |||||
| 6-1 Month Momentum % | 19.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.29 | |||||
| Quick Ratio | 5.29 | |||||
| Cash Ratio | 4.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.8 | |||||
| Shareholder Yield % | -0.01 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -76.75 | |||||
| ROA % | -41.38 | |||||
| ROIC % | -205.22 | |||||
| ROC (Joel Greenblatt) % | -3902.05 | |||||
| ROCE % | -49.72 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.01 | |||||
| Price-to-Tangible-Book | 4.57 | |||||
| EV-to-EBIT | -8.26 | |||||
| EV-to-Forward-EBIT | -4.27 | |||||
| EV-to-EBITDA | -8.3 | |||||
| EV-to-Forward-EBITDA | -4.27 | |||||
| EV-to-Forward-Revenue | 234.93 | |||||
| EV-to-FCF | -6.32 | |||||
| Price-to-Net-Current-Asset-Value | 4.63 | |||||
| Price-to-Net-Cash | 5.24 | |||||
| Earnings Yield (Greenblatt) % | -12.1 | |||||
| FCF Yield % | -12.55 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oculis Holding AG Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.252 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 55.59 | ||
| 14-Day ATR (€) | 0.217697 | ||
| 20-Day SMA (€) | 10.675 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 8.5 - 12.8 | ||
| Shares Outstanding (Mil) | 41.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oculis Holding AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oculis Holding AG Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Oculis Holding AG Frequently Asked Questions
What is Oculis Holding AG(FRA:CR5)'s stock price today?
The current price of FRA:CR5 is €11.10. The 52 week high of FRA:CR5 is €12.80 and 52 week low is €8.50.
When is next earnings date of Oculis Holding AG(FRA:CR5)?
The next earnings date of Oculis Holding AG(FRA:CR5) is 2024-06-18 Est..
Does Oculis Holding AG(FRA:CR5) pay dividends? If so, how much?
Oculis Holding AG(FRA:CR5) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers